- Home
- TSBK vs CLLS Comparison
TSBK vs CLLS Comparison
Compare TSBK & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSBK
- CLLS
- Stock Information
- Founded
- TSBK 1915
- CLLS 1999
- Country
- TSBK United States
- CLLS France
- Employees
- TSBK N/A
- CLLS N/A
- Industry
- TSBK Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- TSBK Finance
- CLLS Health Care
- Exchange
- TSBK Nasdaq
- CLLS Nasdaq
- Market Cap
- TSBK 251.1M
- CLLS 143.4M
- IPO Year
- TSBK 1998
- CLLS 2007
- Fundamental
- Price
- TSBK $32.32
- CLLS $1.59
- Analyst Decision
- TSBK
- CLLS Buy
- Analyst Count
- TSBK 0
- CLLS 1
- Target Price
- TSBK N/A
- CLLS $4.00
- AVG Volume (30 Days)
- TSBK 11.5K
- CLLS 48.2K
- Earning Date
- TSBK 07-22-2025
- CLLS 08-05-2025
- Dividend Yield
- TSBK 3.22%
- CLLS N/A
- EPS Growth
- TSBK 6.24
- CLLS N/A
- EPS
- TSBK 3.25
- CLLS N/A
- Revenue
- TSBK $76,813,000.00
- CLLS $54,747,000.00
- Revenue This Year
- TSBK N/A
- CLLS $48.52
- Revenue Next Year
- TSBK N/A
- CLLS $5.17
- P/E Ratio
- TSBK $9.99
- CLLS N/A
- Revenue Growth
- TSBK 2.71
- CLLS 351.26
- 52 Week Low
- TSBK $25.75
- CLLS $1.10
- 52 Week High
- TSBK $33.98
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- TSBK 58.79
- CLLS 56.98
- Support Level
- TSBK $31.66
- CLLS $1.56
- Resistance Level
- TSBK $32.42
- CLLS $1.49
- Average True Range (ATR)
- TSBK 0.75
- CLLS 0.09
- MACD
- TSBK 0.11
- CLLS 0.01
- Stochastic Oscillator
- TSBK 90.70
- CLLS 80.00
About TSBK Timberland Bancorp Inc.
Timberland Bancorp Inc is a bank holding company. It has one reportable operating segment which is defined as community banking in western Washington under the operating name Timberland Bank. The bank offers a variety of services such as checking accounts, online and mobile banking, savings accounts, home loans, consumer loans, construction loans, business rewards, cash management, small business solutions, and business checking accounts among others. It also offers loans to real estate, including residential and commercial, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.